The response to a range of small doses of suxamethonium was evaluated in a patient with an atypical plasma cholinesterase who required a course of electroconvulsive therapy. A dose of 0.05-0.1 mg/kg of suxamethonium is suggested as a suitable test dose in patients suspected of having an atypical plasma cholinesterase.
Suxamethonium is usually avoided in patients known to have an atypical plasma cholinesterase, and relatively little is known about the effects of small doses of suxamethonium in such patients. This information has considerable bearing on the size of a test dose of suxamethonium in patients suspected of having an atypical plasma cholinesterase. Therefore, we have documented the response to a range of small doses of suxamethonium in a patient with an atypical plasma cholinesterase who required repeated anaesthesia for electroconvulsive therapy (ECT).
CASE REPORT A 56-year-old woman weighing 50 kg was in normal physical health when she presented with endogenous depression for ECT. Her only medication was nitrazepam 5 mg at night.
Both she and her sister had had previous episodes of prolonged paralysis following suxamethonium. Investigation revealed a plasma cholinesterase level of 2.59 ull (normal 1.44-3.50 u/l) with a dibucaine number of 20, suggesting a genotype of E~E~ (DD) or E~E:
(DS)Y
Although plasma cholinesterase concentrate is available,3 it has not been approved for use in Australia. Therefore, with the informed consent of the patient, we decided to use small doses of suxamethonium for the ECT, measuring the response by recording depression of the adductor pollicis isometric twitch tension.
Methods
Anaesthesia was induced with thiopentone 4-5 mg/kg and maintained with 1 mglkg supplements. Atropine 0.4 mg was given to suppress excess salivation, and oxygen given by face mask. A force-displacement transducer was attached to the right hand to measure the isometric twitch tension of the adductor pollicis muscle, resulting from supramaximal stimulation of the ulnar nerve at the wrist at a frequency of 0.1 Hz. The isometric twitch tension was recorded on a Devices 2-channel chart recorder.
After control values were established, suxamethonium was given into the left cephalic vein at the wrist or elbow as a bolus dose. The suxamethonium was diluted and the needle flushed with saline to ensure accurate dosage. Respiration was assisted by intermittent positive pressure ventilation, and endotracheal intubation employed when paralysis was extensive and prolonged following the larger doses of suxamethonium. Nitrous oxide was added to ensure anaesthesia until full recovery from muscle paralysis.
A single dose of suxamethonium was given for each ECT treatment. After doses of suxamethonium 2.5, 3.0, 3.5 and 5.0 mg given on four separate occasions, the following variables were measured to the nearest 0.5 minute. These variables, as defined below, are illustrated in Figure 1 . A. Time to onset of paralysis. Time from injection to beginning of depression of twitch tension. B. Time from lllJection to maximum depression of twitch tension. C. Maximum depression of twitch tension (as a percentage of control twitch response). D. Recovery time. Time for recovery from 80% depression to 20% depression of twitch tension. E. Duration of action. Time from onset of twitch depression to full recovery of control twitch tension. On the occasion that the initial dose of suxamethonium was 2.5 mg paralysis was considered inadequate for ECT, and three further increments of 0.5 mg were given. On this occasion the integrated electromyogram (IEMG) was also measured using surface electrodes placed over the thenar eminence of the left hand. 
Results
Table shows the results of the administration of 2.5, 3.0, 3.5 and 5.0 mg of suxamethonium. In this patient doses of 3.5 and 5.0 mg produced greater than 90070 twitch depression, with full recovery occurring within 30 minutes.
In all cases the onset of twitch depression was preceded by augmentation of twitch tension, and twitch tension recovery occurred to greater than control levels. Approximately 90% depression of twitch tension was found adequate to modify the convulsion, and it was noted at this level of paralysis that spontaneous respiratory movements still appeared to be clinically adequate. There were no visible fasciculations and the patient denied experiencing muscle pains after any administration of suxamethonium. initial 2.5 mg dose (where more than 2 minutes elapsed before a response was seen). 95070 depression of twitch tension resulted from this dose of 4 mg of suxamethonium given in divided doses over a 15 minute period.
DISCUSSION
Relatively little information is available in the literature about the magnitude and duration of the effects of small doses of suxamethonium in patients with an atypical plasma cholinesterase. Considerable variation exists in recommended test doses of suxamethonium and the effects reported to follow these small doses.
Katz and Katz 4 reported that the duration of apnoea in patients with an atypical plasma cholinesterase was 13 minutes after 10 mg, and 31 minutes after 40 mg of suxamethonium. Pantuck and Pantuck 1 suggested that a test dose of 10-20 mg would produce little risk of markedly prolonged apnoea. Ali and Savarese 5 suggested that the occurrence of profound paralysis or apnoea lasting longer than 5 minutes following a test dose of 0.05-0.1 mg/kg of suxamethonium in the anaesthetised spontaneously breathing patient would suggest a plasma cholinesterase disorder. Cohen, Reynolds and Naidl 6 found that a dose of 1 mg of suxamethonium produced a marked impairment of twitch tension and apnoea for 5 minutes in an adult female with genotype E~E~ Anaesthesia and Intensive Care, Vol. X, No. 1, February, 1982 Baraka 7 reported that 0.1 mg/kg of suxamethonium given to a child of genotype E~E~ produced 100% paralysis with the total duration of paralysis approximately 17 minutes. Lee-Son et al. 8 studied an 80-year-old man with an atypical cholinesterase during a course of ECT and determined that in this man the ED50 for suxamethonium was 67.5 !.Ig/kg. When suxamethonium was given in incremental doses the cumulative dose for 90% depression of twitch response was 6-8 mg, with twitch responses returning to 75% of control values in 20-28 minutes. Our results agree closely with the latter two studies.
Presumably much of this variation can be explained by differences in individual patient responses to a given dose of suxamethonium, similar to differences in muscle paralysis produced in a population by a dose of nondepolarising relaxant. 4 It would seem that 0.05-0.1 mg/kg is a suitable test dose of suxamethonium, and that ideally the effects of this dose should be assessed by a peripheral nerve stimulator, as significant paralysis may occur with the smaller range of dosage in the absence of apnoea.
Several other features of this study were of interest. With each initial dose of suxamethonium an increase in mechanical twitch tension preceded the onset of paralysis, and the twitch tension subsequently recovered to a level greater than the control value. A similar initial increase in the IEMG is also seen in Figure 2 . The return of the IEMG to a level less than control is thought to be due to a change in skin conduction under the recording electrodes. These phenomena, together with differences between the mechanical and electrical events induced by suxamethonium, as also noted in our patient, have been described previously.9,10 Although 0.1 mg/kg of suxamethonium gave about 20 minutes of adequate surgical paralysis in a patient with atypical cholinesterase, the onset of paralysis was slow (about 6 minutes) compared with the rapid onset following 1 mg/kg in normal patients. This suggests that this dose of suxamethonium would be useless for rapid intubation in anaesthesia for surgical emergencies.
